Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dynamic Valence-State-Adaptive Ta Single-Atom Sites for Artificial H<sub>2</sub>O<sub>2</sub> Photosynthesis.

Journal of the American Chemical Society·2026

Same author

Discovery of sulfonyl benzoic acid derivatives with joint TGR5-agonist and FXR-antagonist activity for myocardial ischemia/reperfusion injury protection.

Acta pharmaceutica Sinica. B·2026

Same author

Distinctly altered TRPC3 and TRPC6 expression patterns in human Alzheimer's disease cortex and hippocampus.

Brain pathology (Zurich, Switzerland)·2026

Same author

Eating disorders among college students in China: prevalence, correlates, and its relationship with suicide risk.

Journal of eating disorders·2026

Same author

miR-29a-3p targets the PI3K/Akt signaling pathway to suppress inflammation and MMP-9-dependent matrix degradation in spinal tuberculosis.

Journal of orthopaedic surgery and research·2026

Same author

Author Correction: Inhibition of fatty acid uptake by TGR5 prevents diabetic cardiomyopathy.

Nature metabolism·2026

Search research articles

Related Experiment Video

Updated: Aug 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

CD25: A potential tumor therapeutic target.

Yujia Peng^1,2,3, Yiran Tao^1,2,3, Ya Zhang^1,4

¹State Key Laboratory of Biotherapy, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease- related Molecular Network, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

International Journal of Cancer

|September 9, 2022

Summary

This summary is machine-generated.

CD25, the alpha-chain of the IL-2 receptor, is crucial in cancer immunotherapy. Targeting CD25 depletes regulatory T cells (Tregs), restoring anti-tumor immune responses and aiding cancer treatment.

Keywords:

CD25 anti-CD25 drugs regulatory T cells tumor immunotherapy

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Aug 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Immunology
Oncology
Pharmacology

Background:

CD25, the alpha-chain of the interleukin-2 (IL-2) receptor, is expressed on various immune cells, including regulatory T cells (Tregs).
High CD25 expression is observed in hematological malignancies and on activated immune cells, while solid tumors show lower expression.
Treg infiltration in the tumor microenvironment disrupts the effector T cell (Teff)/Treg ratio, promoting cancer progression.

Purpose of the Study:

To review the structure and function of the IL-2 receptor (IL-2R) and CD25.
To elucidate the role of CD25 in tumor biology and cancer immunotherapy.
To summarize recent advancements in drugs targeting CD25 for therapeutic development.

Main Methods:

Literature review on CD25 expression in various cancers and immune cells.
Analysis of the biological functions of CD25 and its impact on the tumor microenvironment.
Synthesis of current research on CD25-targeting drugs and their therapeutic potential.

Main Results:

CD25 is a key marker for Tregs, whose accumulation in tumors impedes anti-tumor immunity.
Restoring the Teff/Treg balance by targeting CD25 is a promising strategy for effective immunotherapy.
Several drugs targeting CD25 are under investigation for their efficacy in cancer treatment.

Conclusions:

CD25 is a critical target for modulating the immune response against cancer.
Depleting Tregs via CD25 targeting can enhance anti-tumor activity and improve immunotherapy outcomes.
Further research into CD25-targeted therapies holds significant promise for future cancer drug development.